Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT04976192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

608

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Urticaria

Interventions

COMBINATION_PRODUCT: TEV-45779
COMBINATION_PRODUCT: XOLAIR® Injection

Sponsor

Teva Pharmaceuticals USA

Collaborators

[object Object]